Published in J Clin Oncol on March 15, 2010
Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol (2009) 1.70
Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis. J Am Acad Dermatol (2013) 1.45
Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2. Breast Cancer (2013) 1.26
Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine. J Transl Med (2011) 1.21
Evidence for rapamycin toxicity in pancreatic β-cells and a review of the underlying molecular mechanisms. Diabetes (2013) 1.17
Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine? Oncologist (2012) 1.10
The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma. Cancers (Basel) (2014) 1.10
Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. Br J Cancer (2012) 1.04
mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice. J Clin Invest (2013) 1.03
Treatment options in patients with metastatic gastric cancer: current status and future perspectives. World J Gastroenterol (2014) 1.02
New perspectives in the treatment of advanced or metastatic gastric cancer. World J Gastroenterol (2009) 1.01
Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors. J Hematol Oncol (2011) 0.97
A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. Breast Cancer Res Treat (2013) 0.97
Molecular targeted agents for gastric and gastroesophageal junction cancer. Surg Today (2011) 0.97
Novel targeted agents for gastric cancer. J Hematol Oncol (2012) 0.96
Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial. J Clin Oncol (2016) 0.93
Clinical management of advanced gastric cancer: the role of new molecular drugs. World J Gastroenterol (2014) 0.92
Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol (2011) 0.92
The progress of targeted therapy in advanced gastric cancer. Biomark Res (2013) 0.89
Metabolic complications with the use of mTOR inhibitors for cancer therapy. Cancer Treat Rev (2013) 0.89
Molecular targeted therapies in advanced gastric cancer: does tumor histology matter? Therap Adv Gastroenterol (2013) 0.87
Molecular targeted agents for gastric cancer: a step forward towards personalized therapy. Cancers (Basel) (2013) 0.87
Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients. Invest New Drugs (2013) 0.86
Second-line treatment of metastatic gastric cancer: Current options and future directions. World J Gastroenterol (2015) 0.86
Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer. Cancer Chemother Pharmacol (2011) 0.86
Targeted therapies in gastric cancer and future perspectives. World J Gastroenterol (2016) 0.86
Molecular targeted therapy for advanced gastric cancer. Korean J Intern Med (2013) 0.84
Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes? Int Neurourol J (2016) 0.84
Molecular targeting to treat gastric cancer. World J Gastroenterol (2014) 0.84
Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression. BMC Cancer (2015) 0.84
Current status of novel agents in advanced gastroesophageal adenocarcinoma. J Gastrointest Oncol (2015) 0.83
Recent updates of precision therapy for gastric cancer: Towards optimal tailored management. World J Gastroenterol (2016) 0.83
Analysis of mTOR inhibition-involved pathway in ovarian clear cell adenocarcinoma. Acta Histochem Cytochem (2011) 0.82
Targeted therapy for advanced gastric cancer: A review of current status and future prospects. World J Gastrointest Oncol (2015) 0.82
Changing strategies for target therapy in gastric cancer. World J Gastroenterol (2016) 0.81
Clinicopathological features and outcomes of patients with gastric cancer: a single-center experience. World J Gastroenterol (2013) 0.81
New advances in targeted gastric cancer treatment. World J Gastroenterol (2016) 0.81
Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma. Cancer Med (2013) 0.80
Gastric biomarkers: a global review. World J Surg Oncol (2016) 0.79
Gastric cancer: The times they are a-changin'. World J Gastrointest Oncol (2015) 0.79
MELD-sodium score and its prognostic value in malignancy-related ascites of pancreatic and gastric cancer. Support Care Cancer (2012) 0.78
Targeted therapies for metastatic esophagogastric cancer. Curr Treat Options Oncol (2011) 0.78
Gastric Cancer: New Drugs - New Strategies. Gastrointest Tumors (2015) 0.78
Genetic mutation analysis of human gastric adenocarcinomas using ion torrent sequencing platform. PLoS One (2014) 0.78
Second-line chemotherapy for gastric cancer: a new issue lies ahead in global trials. Gastric Cancer (2011) 0.78
Targeted therapies in gastric cancer treatment: where we are and where we are going. Invest New Drugs (2016) 0.77
Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical Application. Gastroenterol Res Pract (2016) 0.77
Angiogenesis inhibitors in gastric and gastroesophageal junction cancer. Gastric Cancer (2015) 0.76
Targeted therapy for esophagogastric cancers: a review. Onco Targets Ther (2012) 0.75
Targeted therapy in gastrointestinal malignancies. J Carcinog (2014) 0.75
HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives. Oncotarget (2016) 0.75
Beyond HER2: recent advances and future directions in targeted therapies in esophagogastric cancers. J Gastrointest Oncol (2016) 0.75
Ramucirumab for the treatment of gastroesophageal cancers. Expert Opin Orphan Drugs (2015) 0.75
Novel Targeted Therapies for Esophagogastric Cancer. Surg Oncol Clin N Am (2017) 0.75
To Excavate Biomarkers Predictive of the Response for Capecitabine plus RAD001 through Nanostring-Based Multigene Assay in Advanced Gastric Cancer Patients. J Cancer (2016) 0.75
Rapamycin and thalidomide treatment of a patient with refractory metastatic gastroesophageal adenocarcinoma: a case report. Oncologist (2010) 0.75
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol (2011) 6.18
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol (2011) 5.39
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol (2009) 5.19
Appearance of enhanced tissue features in narrow-band endoscopic imaging. J Biomed Opt (2004) 5.16
TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol (2012) 4.19
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol (2013) 3.26
Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med (2015) 3.09
Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet (2008) 2.89
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol (2010) 2.73
Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol (2015) 2.70
Squamous cell carcinoma in situ at oropharyngeal and hypopharyngeal mucosal sites. Cancer (2004) 2.67
Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol (2013) 2.45
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol (2012) 2.45
Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol (2003) 2.31
Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol (2013) 2.14
UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther (2004) 2.14
Efficacy of a multi-metric fish index as an analysis tool for the transitional fish component of the Water Framework Directive. Mar Pollut Bull (2006) 2.10
Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics (2007) 2.01
FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth. Cancer Res (2010) 1.99
Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep (2006) 1.91
Perceptions and attitudes of clinical oncologists on complementary and alternative medicine: a nationwide survey in Japan. Cancer (2003) 1.82
Esophageal stenosis after endoscopic mucosal resection of superficial esophageal lesions. Gastrointest Endosc (2003) 1.82
A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol (2006) 1.81
Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys (2010) 1.71
Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer. Gastric Cancer (2002) 1.71
Photodynamic therapy as salvage treatment for local failures after definitive chemoradiotherapy for esophageal cancer. Gastrointest Endosc (2005) 1.71
A new technique for endoscopic mucosal resection with an insulated-tip electrosurgical knife improves the completeness of resection of intramucosal gastric neoplasms. Gastrointest Endosc (2002) 1.70
Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med (2010) 1.66
Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci (2010) 1.62
Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer (2006) 1.60
A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol (2007) 1.59
Association of multiple Lugol-voiding lesions with synchronous and metachronous esophageal squamous cell carcinoma in patients with head and neck cancer. Gastrointest Endosc (2002) 1.55
Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01). Jpn J Clin Oncol (2008) 1.55
Efficacy of preventive endoscopic balloon dilation for esophageal stricture after endoscopic resection. J Clin Gastroenterol (2011) 1.47
Reporting patient characteristics and stratification factors in randomized trials of systemic chemotherapy for advanced gastric cancer. Gastric Cancer (2011) 1.45
S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol (2008) 1.44
Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma. Cancer (2004) 1.44
A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Jpn J Clin Oncol (2007) 1.41
AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor. Clin Cancer Res (2007) 1.41
Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. Clin Cancer Res (2011) 1.41
Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol (2015) 1.39
Phase I/II study of radiologic hepatic arterial infusion of fluorouracil plus systemic irinotecan for unresectable hepatic metastases from colorectal cancer: Japan Clinical Oncology Group Trial 0208-DI. J Vasc Interv Radiol (2012) 1.38
mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells. Cancer Res (2009) 1.36
Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma. Gastric Cancer (2011) 1.35
Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer. J Gastroenterol (2009) 1.34
Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol (2006) 1.34
Local recurrence of squamous-cell carcinoma of the esophagus after EMR. Gastrointest Endosc (2005) 1.34
Risk of multiple squamous cell carcinomas both in the esophagus and the head and neck region. Carcinogenesis (2005) 1.32
Gastric Cancer Working Group report. Jpn J Clin Oncol (2010) 1.31
Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. Cancer Sci (2014) 1.30
Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer. Jpn J Clin Oncol (2005) 1.29
Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis. J Natl Cancer Inst (2013) 1.28
Hexabromocyclododecanes in indoor dust from Canada, the United Kingdom, and the United States. Environ Sci Technol (2008) 1.28
Elective nodal irradiation (ENI) in definitive chemoradiotherapy (CRT) for squamous cell carcinoma of the thoracic esophagus. Radiother Oncol (2008) 1.28
Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. Cancer (2011) 1.27
Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study. Jpn J Clin Oncol (2004) 1.26
Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3)N(any) M(0) squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys (2003) 1.25
Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs (2010) 1.25
Palliative radiotherapy for bleeding from advanced gastric cancer: is a schedule of 30 Gy in 10 fractions adequate? J Cancer Res Clin Oncol (2010) 1.24
Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma. Cancer Sci (2013) 1.22
Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors. Jpn J Clin Oncol (2009) 1.21
SRPX2 is overexpressed in gastric cancer and promotes cellular migration and adhesion. Int J Cancer (2009) 1.21
Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate. Invest New Drugs (2010) 1.21